{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:19:11Z","timestamp":1794374351791,"version":"4.9.0"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tianjin Health Research Project","award":["Grant No. TJWJ2024QN040"],"award-info":[{"award-number":["Grant No. TJWJ2024QN040"]}]},{"name":"The major special project on public health science and technology in Tianjin","award":["24ZXGZSY00120"],"award-info":[{"award-number":["24ZXGZSY00120"]}]},{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project","award":["TJYXZDXK-056B"],"award-info":[{"award-number":["TJYXZDXK-056B"]}]},{"name":"the Science and Technology Project of Tianjin Municipal Health Committee","award":["TJWJ2022XK018, TJWJ2022QN030"],"award-info":[{"award-number":["TJWJ2022XK018, TJWJ2022QN030"]}]},{"name":"Tianjin key Clinical Specialty Construction Project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nowadays, chimeric antigen receptor (CAR) -T cell therapy has shown significant efficacy in treating hematological tumors, with an obvious increase in patient survival rates. However, with the widespread application of CAR-T, the incidence of CAR-T related adverse events has gradually increased, including cytokine release syndrome (CRS), immune effector cell associated neurotoxicity syndrome (ICANS), and hemophagocytic lymphohistiocytosis (HLH). These complications may be life-threatening, so early diagnosis and intervention treatment are crucial for the prognosis of patients. In this review, we first comprehensively summarize the latest insights into the pathogenesis and clinical manifestations of CRS, ICANS, and HLH after CAR-T, with a focus on elaborating on the specific mechanisms and related pathways of the inflammatory storm caused by a large number of cytokines after CAR-T. We also discussed the established prevention and management strategies for the three complications mentioned above, and demonstrated the effectiveness of the treatment by introducing the therapeutic effects of various treatment methods in current clinical or preclinical trials. In addition, we provide a prospective perspective on the measures and modifications currently being studied to mitigate the toxicity associated with CAR-T cell therapy.<\/jats:p>","DOI":"10.1007\/s00277-025-06467-y","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T05:34:59Z","timestamp":1750311299000},"page":"3129-3151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Latest updates on pathogenesis mechanisms and management strategies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis related to CAR-T cell therapies"],"prefix":"10.1007","volume":"104","author":[{"given":"Xin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jile","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"issue":"1","key":"6467_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-023-01409-5","volume":"16","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N, Haddad FG, Welch MA, Ravandi F, Kantarjian H (2023) The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol 16(1):22. https:\/\/doi.org\/10.1186\/s13045-023-01409-5","journal-title":"J Hematol Oncol"},{"issue":"7926","key":"6467_CR2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","volume":"609","author":"J Zhang","year":"2022","unstructured":"Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, Zhang L, Wei G, Tian Y, Zhao K, Chen A, Tan B, Cui J, Li D, Li Y, Qi Y, Wang D, Wu Y, Li D, Du B, Liu M, Huang H (2022) Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature 609(7926):369\u2013374. https:\/\/doi.org\/10.1038\/s41586-022-05140-y","journal-title":"Nature"},{"issue":"1","key":"6467_CR3","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","volume":"15","author":"M Shi","year":"2024","unstructured":"Shi M, Wang J, Huang H, Liu D, Cheng H, Wang X, Chen W, Yan Z, Sang W, Qi K, Li D, Zhu F, Li Z, Qiao J, Wu Q, Zeng L, Fei X, Gu W, Miao Y, Xu K, Zheng J, Cao J (2024) Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial. Nat Commun 15(1):3371. https:\/\/doi.org\/10.1038\/s41467-024-47801-8","journal-title":"Nat Commun"},{"issue":"1","key":"6467_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, M\u00fcller-Tidow C, Dreger P (2021) Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol 32(1):34\u201348. https:\/\/doi.org\/10.1016\/j.annonc.2020.10.478","journal-title":"Ann Oncol"},{"issue":"5","key":"6467_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378(5):439\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa1709866","journal-title":"N Engl J Med"},{"issue":"26","key":"6467_CR6","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"issue":"19","key":"6467_CR7","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF, Xu J, Zhuang Y, Zhang W, Weng XQ, Wu J, Wang Y, Wang J, Yan H, Xu WB, Jiang H, Du J, Ding XY, Li B, Li JM, Fu WJ, Zhu J, Zhu L, Chen Z, Fan XF, Hou J, Li JY, Mi JQ, Chen SJ (2019) Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc Natl Acad Sci U S A 116(19):9543\u20139551. https:\/\/doi.org\/10.1073\/pnas.1819745116","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"6467_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, Li Y (2021) Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res 40(1):367. https:\/\/doi.org\/10.1186\/s13046-021-02148-6","journal-title":"J Exp Clin Cancer Res"},{"issue":"17","key":"6467_CR9","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1200\/jco.19.03279","volume":"38","author":"NN Shah","year":"2020","unstructured":"Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL, Ombrello A, Steinberg SM, Martin S, Delbrook C, Hoffman L, Little L, Ponduri A, Qin H, Qureshi H, Dulau-Florea A, Salem D, Wang HW, Yuan C, Stetler-Stevenson M, Panch S, Tran M, Mackall CL, Stroncek DF, Fry TJ (2020) CD4\/CD8 T-Cell selection affects chimeric antigen receptor (CAR) T-Cell potency and toxicity: updated results from a phase I Anti-CD22 CAR T-Cell trial. J Clin Oncol: Off J Am Soc Clin Oncol 38(17):1938\u20131950. https:\/\/doi.org\/10.1200\/jco.19.03279","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"24","key":"6467_CR10","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1182\/blood.2021011898","volume":"138","author":"DA Lichtenstein","year":"2021","unstructured":"Lichtenstein DA, Schischlik F, Shao L, Steinberg SM, Yates B, Wang HW, Wang Y, Inglefield J, Dulau-Florea A, Ceppi F, Hermida LC, Stringaris K, Dunham K, Homan P, Jailwala P, Mirazee J, Robinson W, Chisholm KM, Yuan C, Stetler-Stevenson M, Ombrello AK, Jin J, Fry TJ, Taylor N, Highfill SL, Jin P, Gardner RA, Shalabi H, Ruppin E, Stroncek DF, Shah NN (2021) Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood 138(24):2469\u20132484. https:\/\/doi.org\/10.1182\/blood.2021011898","journal-title":"Blood"},{"key":"6467_CR11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fimmu.2020.00524","volume":"11","author":"RD Sandler","year":"2020","unstructured":"Sandler RD, Tattersall RS, Schoemans H, Greco R, Badoglio M, Labopin M, Alexander T, Kirgizov K, Rovira M, Saif M, Saccardi R, Delgado J, Peric Z, Koenecke C, Penack O, Basak G, Snowden JA (2020) Diagnosis and management of secondary HLH\/MAS following HSCT and CAR-T cell therapy in adults; A review of the literature and a survey of practice within EBMT centres on behalf of the autoimmune diseases working party (ADWP) and transplant complications working party (TCWP). Front Immunol 11:524. https:\/\/doi.org\/10.3389\/fimmu.2020.00524","journal-title":"Front Immunol"},{"issue":"3","key":"6467_CR12","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12185-009-0261-1","volume":"89","author":"A Abdelkefi","year":"2009","unstructured":"Abdelkefi A, Jamil WB, Torjman L, Ladeb S, Ksouri H, Lakhal A, Hassen AB, Abdeladhim AB, Othman TB (2009) Hemophagocytic syndrome after hematopoietic stem cell transplantation: a prospective observational study. Int J Hematol 89(3):368\u2013373. https:\/\/doi.org\/10.1007\/s12185-009-0261-1","journal-title":"Int J Hematol"},{"issue":"5","key":"6467_CR13","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41409-019-0711-1","volume":"55","author":"RM Alblooshi","year":"2020","unstructured":"Alblooshi RM, Deotare U, Michelis FV, Thyagu S, Kim DDH, Lipton JH, ElGohary GM, Viswabandya A (2020) My Jamais Vu in post allogeneic hematopoietic cell transplant: a review on secondary hemophagocytosis in adults. Bone Marrow Transpl 55(5):867\u2013872. https:\/\/doi.org\/10.1038\/s41409-019-0711-1","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"6467_CR14","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R (2018) FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-Induced severe or life-threatening cytokine release syndrome. Oncologist 23(8):943\u2013947. https:\/\/doi.org\/10.1634\/theoncologist.2018-0028","journal-title":"Oncologist"},{"issue":"2","key":"6467_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M (2022) Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 22(2):85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"6467_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1158\/2643-3230.Bcd-21-0203","volume":"3","author":"KO McNerney","year":"2022","unstructured":"McNerney KO, DiNofia AM, Teachey DT, Grupp SA, Maude SL (2022) Potential role of IFN\u03b3 Inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy. Blood Cancer Discov 3(2):90\u201394. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-21-0203","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"6467_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper DJ, Balkwill FR (2022) Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol 19(4):237\u2013253. https:\/\/doi.org\/10.1038\/s41571-021-00588-9","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"6467_CR18","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","volume":"146","author":"CW Freyer","year":"2020","unstructured":"Freyer CW, Porter DL (2020) Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol 146(5):940\u2013948. https:\/\/doi.org\/10.1016\/j.jaci.2020.07.025","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"6467_CR19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.canlet.2013.10.004","volume":"343","author":"XJ Xu","year":"2014","unstructured":"Xu XJ, Tang YM (2014) Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. Cancer Lett 343(2):172\u2013178. https:\/\/doi.org\/10.1016\/j.canlet.2013.10.004","journal-title":"Cancer Lett"},{"issue":"4","key":"6467_CR20","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","volume":"25","author":"N Frey","year":"2019","unstructured":"Frey N, Porter D (2019) Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transpl 25(4):e123\u2013e127. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.756","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10s","key":"6467_CR21","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.bulcan.2021.05.003","volume":"108","author":"F Wallet","year":"2021","unstructured":"Wallet F, Sesques P, Devic P, Levrard M, Ader F, Friggeri A, Bachy E (2021) CAR-T cell: toxicities issues: mechanisms and clinical management. Bull Cancer 108(10s):S117\u2013s127. https:\/\/doi.org\/10.1016\/j.bulcan.2021.05.003","journal-title":"Bull Cancer"},{"issue":"2","key":"6467_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","volume":"141","author":"X Yao","year":"2014","unstructured":"Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, Yao Y (2014) Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther 141(2):125\u2013139. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.09.004","journal-title":"Pharmacol Ther"},{"issue":"4","key":"6467_CR23","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","volume":"50","author":"S Kang","year":"2019","unstructured":"Kang S, Tanaka T, Narazaki M, Kishimoto T (2019) Targeting Interleukin-6 signaling in clinic. Immunity 50(4):1007\u20131023. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.026","journal-title":"Immunity"},{"issue":"224","key":"6467_CR24","doi-asserted-by":"publisher","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6(224):224ra225. https:\/\/doi.org\/10.1126\/scitranslmed.3008226","journal-title":"Sci Transl Med"},{"key":"6467_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-020-00171-5","volume":"9","author":"Z Hao","year":"2020","unstructured":"Hao Z, Li R, Meng L, Han Z, Hong Z (2020) Macrophage, the potential key mediator in CAR-T related CRS. Exp Hematol Oncol 9:15. https:\/\/doi.org\/10.1186\/s40164-020-00171-5","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"6467_CR26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrd.2018.45","volume":"17","author":"C Garbers","year":"2018","unstructured":"Garbers C, Heink S, Korn T, Rose-John S (2018) Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov 17(6):395\u2013412. https:\/\/doi.org\/10.1038\/nrd.2018.45","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"6467_CR27","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M (2018) CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 Blockade. Nat Med 24(6):731\u2013738. https:\/\/doi.org\/10.1038\/s41591-018-0041-7","journal-title":"Nat Med"},{"issue":"6","key":"6467_CR28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, Sanvito F, Ponzoni M, Doglioni C, Cristofori P, Traversari C, Bordignon C, Ciceri F, Ostuni R, Bonini C, Casucci M, Bondanza A (2018) Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24(6):739\u2013748. https:\/\/doi.org\/10.1038\/s41591-018-0036-4","journal-title":"Nat Med"},{"issue":"2","key":"6467_CR29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2):188\u2013195. https:\/\/doi.org\/10.1182\/blood-2014-05-552729","journal-title":"Blood"},{"issue":"3","key":"6467_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10555-006-9004-4","volume":"25","author":"RN Apte","year":"2006","unstructured":"Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E (2006) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25(3):387\u2013408. https:\/\/doi.org\/10.1007\/s10555-006-9004-4","journal-title":"Cancer Metastasis Rev"},{"issue":"8","key":"6467_CR31","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nrd3800","volume":"11","author":"CA Dinarello","year":"2012","unstructured":"Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11(8):633\u2013652. https:\/\/doi.org\/10.1038\/nrd3800","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"6467_CR32","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson KV, Deng M, Ting JP (2019) The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol 19(8):477\u2013489. https:\/\/doi.org\/10.1038\/s41577-019-0165-0","journal-title":"Nat Rev Immunol"},{"key":"6467_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/itt.S202015","volume":"8","author":"H Murthy","year":"2019","unstructured":"Murthy H, Iqbal M, Chavez JC, Kharfan-Dabaja MA (2019) Cytokine release syndrome: current perspectives. ImmunoTargets Therapy 8:43\u201352. https:\/\/doi.org\/10.2147\/itt.S202015","journal-title":"ImmunoTargets Therapy"},{"issue":"4","key":"6467_CR34","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.immuni.2019.03.012","volume":"50","author":"A Mantovani","year":"2019","unstructured":"Mantovani A, Dinarello CA, Molgora M, Garlanda C (2019) Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity 50(4):778\u2013795. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.012","journal-title":"Immunity"},{"issue":"12","key":"6467_CR35","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1158\/2159-8290.Cd-17-1084","volume":"7","author":"CL Mackall","year":"2017","unstructured":"Mackall CL, Miklos DB (2017) CNS endothelial cell activation emerges as a driver of CAR T cell-Associated neurotoxicity. Cancer Discov 7(12):1371\u20131373. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-1084","journal-title":"Cancer Discov"},{"issue":"21","key":"6467_CR36","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, L\u00f3pez JA, Chen J, Chung D, Harju-Baker S, Cherian S, Chen X, Riddell SR, Maloney DG, Turtle CJ (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130(21):2295\u20132306. https:\/\/doi.org\/10.1182\/blood-2017-06-793141","journal-title":"Blood"},{"issue":"14","key":"6467_CR37","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","volume":"117","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117(14):3720\u20133732. https:\/\/doi.org\/10.1182\/blood-2010-07-273417","journal-title":"Blood"},{"issue":"12","key":"6467_CR38","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.Cd-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, Yeung C, Liles WC, Wurfel M, Lopez JA, Chen J, Chung D, Harju-Baker S, \u00d6zpolat T, Fink KR, Riddell SR, Maloney DG, Turtle CJ (2017) Endothelial activation and Blood-Brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 7(12):1404\u20131419. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0698","journal-title":"Cancer Discov"},{"issue":"5","key":"6467_CR39","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/eji.201141550","volume":"41","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA (2011) A clinical perspective of IL-1\u03b2 as the gatekeeper of inflammation. Eur J Immunol 41(5):1203\u20131217. https:\/\/doi.org\/10.1002\/eji.201141550","journal-title":"Eur J Immunol"},{"key":"6467_CR40","doi-asserted-by":"publisher","first-page":"623610","DOI":"10.3389\/fimmu.2021.623610","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen Y, Li R, Shang S, Yang X, Li L, Wang W, Wang Y (2021) Therapeutic potential of TNF\u03b1 and IL1\u03b2 Blockade for CRS\/ICANS in CAR-T therapy via ameliorating endothelial activation. Front Immunol 12:623610. https:\/\/doi.org\/10.3389\/fimmu.2021.623610","journal-title":"Front Immunol"},{"issue":"1","key":"6467_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00262-006-0159-1","volume":"56","author":"E Ersvaer","year":"2007","unstructured":"Ersvaer E, Skavland J, Ulvestad E, Gjertsen BT, Bruserud \u00d8 (2007) Effects of interferon gamma on native human acute myelogenous leukaemia cells. Cancer Immunol Immunother 56(1):13\u201324. https:\/\/doi.org\/10.1007\/s00262-006-0159-1","journal-title":"Cancer Immunol Immunother"},{"key":"6467_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","volume":"8","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic D, Song M, Wang L, Zhang Y (2020) Roles of IFN-\u03b3 in tumor progression and regression: a review. Biomark Res 8:49. https:\/\/doi.org\/10.1186\/s40364-020-00228-x","journal-title":"Biomark Res"},{"issue":"8","key":"6467_CR43","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.it.2021.06.001","volume":"42","author":"R Karki","year":"2021","unstructured":"Karki R, Kanneganti TD (2021) The \u2018cytokine storm\u2019: molecular mechanisms and therapeutic prospects. Trends Immunol 42(8):681\u2013705. https:\/\/doi.org\/10.1016\/j.it.2021.06.001","journal-title":"Trends Immunol"},{"issue":"1","key":"6467_CR44","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","volume":"184","author":"R Karki","year":"2021","unstructured":"Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P, Zheng M, Sundaram B, Banoth B, Malireddi RKS, Schreiner P, Neale G, Vogel P, Webby R, Jonsson CB, Kanneganti TD (2021) Synergism of TNF-\u03b1 and IFN-\u03b3 triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 184(1):149\u2013168e117. https:\/\/doi.org\/10.1016\/j.cell.2020.11.025","journal-title":"Cell"},{"key":"6467_CR45","doi-asserted-by":"publisher","unstructured":"Zhou Z, He H, Wang K, Shi X, Wang Y, Su Y, Wang Y, Li D, Liu W, Zhang Y, Shen L, Han W, Shen L, Ding J, Shao F (2020) Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science 368(6494). https:\/\/doi.org\/10.1126\/science.aaz7548","DOI":"10.1126\/science.aaz7548"},{"issue":"3\u20134","key":"6467_CR46","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s10495-023-01925-2","volume":"29","author":"P Zhang","year":"2024","unstructured":"Zhang P, Ying P, Li H, Zhao N, Liu R, Li S, Xu W, Tang Y, Tang Y (2024) A novel safer CD19CAR with ShRNA interference of IFN-\u03b3 can reduce multiple cytokine levels without significantly compromising its killing efficacy. Apoptosis 29(3\u20134):556\u2013567. https:\/\/doi.org\/10.1007\/s10495-023-01925-2","journal-title":"Apoptosis"},{"issue":"2","key":"6467_CR47","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3892\/ol.2024.14817","volume":"29","author":"W Cai","year":"2025","unstructured":"Cai W, Lu Y, He H, Li J, Liu S, Geng H, Yang Q, Zeng L, Wu D, Li C (2025) Efficacy of emapalumab in the management of anti\u2013CD19 chimeric antigen receptor T\u2013cell therapy\u2013associated cytokine release syndrome: a report of two cases. Oncol Lett 29(2):71. https:\/\/doi.org\/10.3892\/ol.2024.14817","journal-title":"Oncol Lett"},{"issue":"9","key":"6467_CR48","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nri1184","volume":"3","author":"BB Aggarwal","year":"2003","unstructured":"Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3(9):745\u2013756. https:\/\/doi.org\/10.1038\/nri1184","journal-title":"Nat Rev Immunol"},{"key":"6467_CR49","doi-asserted-by":"publisher","unstructured":"Li J, Piskol R, Ybarra R, Chen YJ, Li J, Slaga D, Hristopoulos M, Clark R, Modrusan Z, Totpal K, Junttila MR, Junttila TT (2019) CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity. Sci Transl Med 11(508). https:\/\/doi.org\/10.1126\/scitranslmed.aax8861","DOI":"10.1126\/scitranslmed.aax8861"},{"key":"6467_CR50","doi-asserted-by":"publisher","first-page":"833967","DOI":"10.3389\/fpubh.2022.833967","volume":"10","author":"Y Guo","year":"2022","unstructured":"Guo Y, Hu K, Li Y, Lu C, Ling K, Cai C, Wang W, Ye D (2022) Targeting TNF-\u03b1 for COVID-19: recent advanced and controversies. Front Public Health 10:833967. https:\/\/doi.org\/10.3389\/fpubh.2022.833967","journal-title":"Front Public Health"},{"issue":"7","key":"6467_CR51","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00011-013-0633-0","volume":"62","author":"H Zelov\u00e1","year":"2013","unstructured":"Zelov\u00e1 H, Ho\u0161ek J (2013) TNF-\u03b1 signalling and inflammation: interactions between old acquaintances. Inflamm Res 62(7):641\u2013651. https:\/\/doi.org\/10.1007\/s00011-013-0633-0","journal-title":"Inflamm Res"},{"issue":"2","key":"6467_CR52","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/bjh.16623","volume":"191","author":"J Wang","year":"2020","unstructured":"Wang J, Mou N, Yang Z, Li Q, Jiang Y, Meng J, Liu X, Deng Q (2020) Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory\/relapsed B acute lymphoblastic leukaemia. Br J Haematol 191(2):212\u2013222. https:\/\/doi.org\/10.1111\/bjh.16623","journal-title":"Br J Haematol"},{"issue":"1","key":"6467_CR53","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40164-021-00209-2","volume":"10","author":"L Zhang","year":"2021","unstructured":"Zhang L, Wang S, Xu J, Zhang R, Zhu H, Wu Y, Zhu L, Li J, Chen L (2021) Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy. Exp Hematol Oncol 10(1):16. https:\/\/doi.org\/10.1186\/s40164-021-00209-2","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"6467_CR54","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.molimm.2013.05.002","volume":"56","author":"A van Nieuwenhuijze","year":"2013","unstructured":"van Nieuwenhuijze A, Koenders M, Roeleveld D, Sleeman MA, van den Berg W, Wicks IP (2013) GM-CSF as a therapeutic target in inflammatory diseases. Mol Immunol 56(4):675\u2013682. https:\/\/doi.org\/10.1016\/j.molimm.2013.05.002","journal-title":"Mol Immunol"},{"key":"6467_CR55","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2147\/itt.S262566","volume":"9","author":"KMC Lee","year":"2020","unstructured":"Lee KMC, Achuthan AA, Hamilton JA (2020) GM-CSF: a promising target in inflammation and autoimmunity. ImmunoTargets Therapy 9:225\u2013240. https:\/\/doi.org\/10.2147\/itt.S262566","journal-title":"ImmunoTargets Therapy"},{"issue":"1","key":"6467_CR56","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4049\/jimmunol.178.1.39","volume":"178","author":"ED Ponomarev","year":"2007","unstructured":"Ponomarev ED, Shriver LP, Maresz K, Pedras-Vasconcelos J, Verthelyi D, Dittel BN (2007) GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J Immunol 178(1):39\u201348. https:\/\/doi.org\/10.4049\/jimmunol.178.1.39","journal-title":"J Immunol"},{"issue":"14","key":"6467_CR57","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1074\/jbc.AC119.007558","volume":"294","author":"M Sachdeva","year":"2019","unstructured":"Sachdeva M, Duchateau P, Depil S, Poirot L, Valton J (2019) Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. J Biol Chem 294(14):5430\u20135437. https:\/\/doi.org\/10.1074\/jbc.AC119.007558","journal-title":"J Biol Chem"},{"issue":"7","key":"6467_CR58","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","volume":"133","author":"RM Sterner","year":"2019","unstructured":"Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Hefazi M, Schick KJ, Walters DK, Ahmed O, Chappell D, Sahmoud T, Durrant C, Nevala WK, Patnaik MM, Pease LR, Hedin KE, Kay NE, Johnson AJ, Kenderian SS (2019) GM-CSF Inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood 133(7):697\u2013709. https:\/\/doi.org\/10.1182\/blood-2018-10-881722","journal-title":"Blood"},{"key":"6467_CR59","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.3389\/fimmu.2019.01265","volume":"10","author":"N Lotfi","year":"2019","unstructured":"Lotfi N, Thome R, Rezaei N, Zhang GX, Rezaei A, Rostami A, Esmaeil N (2019) Roles of GM-CSF in the pathogenesis of autoimmune diseases: an update. Front Immunol 10:1265. https:\/\/doi.org\/10.3389\/fimmu.2019.01265","journal-title":"Front Immunol"},{"issue":"5","key":"6467_CR60","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1007\/s10753-018-0825-4","volume":"41","author":"S Katz","year":"2018","unstructured":"Katz S, Zsiros V, D\u00f3czi N, Kiss AL (2018) Inflammation-Induced Epithelial-to-Mesenchymal transition and GM-CSF treatment stimulate mesenteric mesothelial cells to transdifferentiate into macrophages. Inflammation 41(5):1825\u20131834. https:\/\/doi.org\/10.1007\/s10753-018-0825-4","journal-title":"Inflammation"},{"key":"6467_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2017.10.016","volume":"267","author":"TC Yang","year":"2017","unstructured":"Yang TC, Chang PY, Kuo TL, Lu SC (2017) Electronegative L5-LDL induces the production of G-CSF and GM-CSF in human macrophages through LOX-1 involving NF-\u03baB and ERK2 activation. Atherosclerosis 267:1\u20139. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.10.016","journal-title":"Atherosclerosis"},{"key":"6467_CR62","doi-asserted-by":"publisher","first-page":"1042501","DOI":"10.3389\/fmed.2022.1042501","volume":"9","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Feng D, Wang C, Zhang Y, Zhao C, Li S, Qin Y, Chang AH, Zhu J (2022) Administration of granulocyte-macrophage colony-stimulating factor enhanced chimeric antigen receptor T-cell expansion and cellular immunity recovery without inducing cytokine release syndrome. Front Med 9:1042501. https:\/\/doi.org\/10.3389\/fmed.2022.1042501","journal-title":"Front Med"},{"key":"6467_CR63","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.3389\/fimmu.2019.02679","volume":"10","author":"Y Zhan","year":"2019","unstructured":"Zhan Y, Lew AM, Chopin M (2019) The pleiotropic effects of the GM-CSF rheostat on myeloid cell differentiation and function: more than a numbers game. Front Immunol 10:2679. https:\/\/doi.org\/10.3389\/fimmu.2019.02679","journal-title":"Front Immunol"},{"issue":"1","key":"6467_CR64","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/imr.12287","volume":"265","author":"I Jorgensen","year":"2015","unstructured":"Jorgensen I, Miao EA (2015) Pyroptotic cell death defends against intracellular pathogens. Immunol Rev 265(1):130\u2013142. https:\/\/doi.org\/10.1111\/imr.12287","journal-title":"Immunol Rev"},{"issue":"3","key":"6467_CR65","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.cell.2017.01.008","volume":"168","author":"J Ding","year":"2017","unstructured":"Ding J, Shao F (2017) SnapShot: the noncanonical inflammasome. Cell 168(3):544\u2013544e541. https:\/\/doi.org\/10.1016\/j.cell.2017.01.008","journal-title":"Cell"},{"issue":"7661","key":"6467_CR66","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature22393","volume":"547","author":"Y Wang","year":"2017","unstructured":"Wang Y, Gao W, Shi X, Ding J, Liu W, He H, Wang K, Shao F (2017) Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature 547(7661):99\u2013103. https:\/\/doi.org\/10.1038\/nature22393","journal-title":"Nature"},{"issue":"4","key":"6467_CR67","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.tibs.2016.10.004","volume":"42","author":"J Shi","year":"2017","unstructured":"Shi J, Gao W, Shao F (2017) Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci 42(4):245\u2013254. https:\/\/doi.org\/10.1016\/j.tibs.2016.10.004","journal-title":"Trends Biochem Sci"},{"key":"6467_CR68","doi-asserted-by":"publisher","unstructured":"Liu Y, Fang Y, Chen X, Wang Z, Liang X, Zhang T, Liu M, Zhou N, Lv J, Tang K, Xie J, Gao Y, Cheng F, Zhou Y, Zhang Z, Hu Y, Zhang X, Gao Q, Zhang Y, Huang B (2020) Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol 5(43). https:\/\/doi.org\/10.1126\/sciimmunol.aax7969","DOI":"10.1126\/sciimmunol.aax7969"},{"issue":"12","key":"6467_CR69","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s41419-023-06382-y","volume":"14","author":"Y Hu","year":"2023","unstructured":"Hu Y, Liu Y, Zong L, Zhang W, Liu R, Xing Q, Liu Z, Yan Q, Li W, Lei H, Liu X (2023) The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting Obstacles. Cell Death Dis 14(12):836. https:\/\/doi.org\/10.1038\/s41419-023-06382-y","journal-title":"Cell Death Dis"},{"issue":"9","key":"6467_CR70","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1002\/jcp.26429","volume":"233","author":"A Shapouri-Moghaddam","year":"2018","unstructured":"Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, Seifi B, Mohammadi A, Afshari JT, Sahebkar A (2018) Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol 233(9):6425\u20136440. https:\/\/doi.org\/10.1002\/jcp.26429","journal-title":"J Cell Physiol"},{"issue":"2","key":"6467_CR71","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","volume":"20","author":"T Gong","year":"2020","unstructured":"Gong T, Liu L, Jiang W, Zhou R (2020) DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol 20(2):95\u2013112. https:\/\/doi.org\/10.1038\/s41577-019-0215-7","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"6467_CR72","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.4110\/in.2018.18.e27","volume":"18","author":"JS Roh","year":"2018","unstructured":"Roh JS, Sohn DH (2018) Damage-Associated molecular patterns in inflammatory diseases. Immune Netw 18(4):e27. https:\/\/doi.org\/10.4110\/in.2018.18.e27","journal-title":"Immune Netw"},{"issue":"1","key":"6467_CR73","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41419-021-03428-x","volume":"12","author":"T Deng","year":"2021","unstructured":"Deng T, Tang C, Zhang G, Wan X (2021) DAMPs released by pyroptotic cells as major contributors and therapeutic targets for CAR-T-related toxicities. Cell Death Dis 12(1):129. https:\/\/doi.org\/10.1038\/s41419-021-03428-x","journal-title":"Cell Death Dis"},{"issue":"9","key":"6467_CR74","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00134-016-4249-z","volume":"42","author":"DT Andreis","year":"2016","unstructured":"Andreis DT, Singer M (2016) Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum. Intensive Care Med 42(9):1387\u20131397. https:\/\/doi.org\/10.1007\/s00134-016-4249-z","journal-title":"Intensive Care Med"},{"issue":"2","key":"6467_CR75","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.trecan.2021.10.005","volume":"8","author":"H Wackerhage","year":"2022","unstructured":"Wackerhage H, Christensen JF, Ilmer M, von Luettichau I, Renz BW, Sch\u00f6nfelder M (2022) Cancer catecholamine conundrum. Trends Cancer 8(2):110\u2013122. https:\/\/doi.org\/10.1016\/j.trecan.2021.10.005","journal-title":"Trends Cancer"},{"issue":"2","key":"6467_CR76","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.it.2022.12.003","volume":"44","author":"X Xing","year":"2023","unstructured":"Xing X, Hu X (2023) Risk factors of cytokine release syndrome: stress, catecholamines, and beyond. Trends Immunol 44(2):93\u2013100. https:\/\/doi.org\/10.1016\/j.it.2022.12.003","journal-title":"Trends Immunol"},{"issue":"7735","key":"6467_CR77","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-018-0774-y","volume":"564","author":"V Staedtke","year":"2018","unstructured":"Staedtke V, Bai RY, Kim K, Darvas M, Davila ML, Riggins GJ, Rothman PB, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S (2018) Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature 564(7735):273\u2013277. https:\/\/doi.org\/10.1038\/s41586-018-0774-y","journal-title":"Nature"},{"key":"6467_CR78","doi-asserted-by":"publisher","unstructured":"Yang Y, Zhang Y, Xing X, Xu G, Lin X, Wang Y, Chen M, Wang C, Zhang B, Han W, Hu X (2023) IL-6 translation is a therapeutic target of human cytokine release syndrome. J Exp Med 220(11). https:\/\/doi.org\/10.1084\/jem.20230577","DOI":"10.1084\/jem.20230577"},{"issue":"4","key":"6467_CR79","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi J, Dietrich J, Straathof K, Roddie C, Scott BJ, Davidson TB, Prolo LM, Batchelor TT, Campen CJ, Davis KL, Gust J, Lim M, Majzner RG, Park JR, Partap S, Ramakrishna S, Richards R, Schultz L, Vitanza NA, Wang LD, Mackall CL, Monje M (2023) Tumor inflammation-associated neurotoxicity. Nat Med 29(4):803\u2013810. https:\/\/doi.org\/10.1038\/s41591-023-02276-w","journal-title":"Nat Med"},{"issue":"6","key":"6467_CR80","doi-asserted-by":"publisher","first-page":"507","DOI":"10.4161\/viru.24530","volume":"4","author":"AV Page","year":"2013","unstructured":"Page AV, Liles WC (2013) Biomarkers of endothelial activation\/dysfunction in infectious diseases. Virulence 4(6):507\u2013516. https:\/\/doi.org\/10.4161\/viru.24530","journal-title":"Virulence"},{"issue":"1","key":"6467_CR81","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/jth.14322","volume":"17","author":"M Schillemans","year":"2019","unstructured":"Schillemans M, Karampini E, Kat M, Bierings R (2019) Exocytosis of Weibel-Palade bodies: how to unpack a vascular emergency kit. J Thromb Haemost 17(1):6\u201318. https:\/\/doi.org\/10.1111\/jth.14322","journal-title":"J Thromb Haemost"},{"issue":"358","key":"6467_CR82","doi-asserted-by":"publisher","first-page":"358ra128","DOI":"10.1126\/scitranslmed.aaf6812","volume":"8","author":"SJ Higgins","year":"2016","unstructured":"Higgins SJ, Purcell LA, Silver KL, Tran V, Crowley V, Hawkes M, Conroy AL, Opoka RO, Hay JG, Quaggin SE, Thurston G, Liles WC, Kain KC (2016) Dysregulation of angiopoietin-1 plays a mechanistic role in the pathogenesis of cerebral malaria. Sci Transl Med 8(358):358ra128. https:\/\/doi.org\/10.1126\/scitranslmed.aaf6812","journal-title":"Sci Transl Med"},{"issue":"1","key":"6467_CR83","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","volume":"183","author":"KR Parker","year":"2020","unstructured":"Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, Haris M, Wilson NE, Liu F, Gabunia K, Scholler J, Montine TJ, Bhoj VG, Reddy R, Mohan S, Maillard I, Kriegstein AR, June CH, Chang HY, Posey AD Jr., Satpathy AT (2020) Single-Cell analyses identify brain mural cells expressing CD19 as potential Off-Tumor targets for CAR-T immunotherapies. Cell 183(1):126\u2013142e117. https:\/\/doi.org\/10.1016\/j.cell.2020.08.022","journal-title":"Cell"},{"issue":"1","key":"6467_CR84","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/cns.13569","volume":"27","author":"X Huang","year":"2021","unstructured":"Huang X, Hussain B, Chang J (2021) Peripheral inflammation and blood-brain barrier disruption: effects and mechanisms. CNS Neurosci Ther 27(1):36\u201347. https:\/\/doi.org\/10.1111\/cns.13569","journal-title":"CNS Neurosci Ther"},{"issue":"8","key":"6467_CR85","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.Cd-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, Cross JR, Liu H, Vachha B, Chen X, DeAngelis LM, Li D, Bernal Y, Gonen M, Wendel HG, Sadelain M, Brentjens RJ (2018) Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 8(8):958\u2013971. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-1319","journal-title":"Cancer Discov"},{"key":"6467_CR86","doi-asserted-by":"publisher","first-page":"577027","DOI":"10.3389\/fimmu.2020.577027","volume":"11","author":"J Gust","year":"2020","unstructured":"Gust J, Ponce R, Liles WC, Garden GA, Turtle CJ (2020) Cytokines in CAR T Cell-Associated neurotoxicity. Front Immunol 11:577027. https:\/\/doi.org\/10.3389\/fimmu.2020.577027","journal-title":"Front Immunol"},{"issue":"16","key":"6467_CR87","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/jco.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, Klebanoff CA, Kammula US, Sherman M, Perez A, Yuan CM, Feldman T, Friedberg JW, Roschewski MJ, Feldman SA, McIntyre L, Toomey MA, Rosenberg SA (2017) Lymphoma remissions caused by Anti-CD19 chimeric antigen receptor T cells are associated with high serum Interleukin-15 levels. J Clin Oncol: Off J Am Soc Clin Oncol 35(16):1803\u20131813. https:\/\/doi.org\/10.1200\/jco.2016.71.3024","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"8","key":"6467_CR88","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1182\/blood-2018-01-828343","volume":"132","author":"J Rossi","year":"2018","unstructured":"Rossi J, Paczkowski P, Shen YW, Morse K, Flynn B, Kaiser A, Ng C, Gallatin K, Cain T, Fan R, Mackay S, Heath JR, Rosenberg SA, Kochenderfer JN, Zhou J, Bot A (2018) Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood 132(8):804\u2013814. https:\/\/doi.org\/10.1182\/blood-2018-01-828343","journal-title":"Blood"},{"issue":"1","key":"6467_CR89","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/imr.13298","volume":"322","author":"MB Jordan","year":"2024","unstructured":"Jordan MB (2024) Hemophagocytic lymphohistiocytosis: a disorder of T cell activation, immune regulation, and distinctive immunopathology. Immunol Rev 322(1):339\u2013350. https:\/\/doi.org\/10.1111\/imr.13298","journal-title":"Immunol Rev"},{"issue":"7","key":"6467_CR90","doi-asserted-by":"publisher","first-page":"438e","DOI":"10.1016\/j.jtct.2023.03.006","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Henter JI, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN (2023) Immune effector Cell-Associated hemophagocytic Lymphohistiocytosis-Like syndrome. Transplantation Cell Therapy 29(7):438e. 431-438.e416","journal-title":"Transplantation Cell Therapy"},{"issue":"1","key":"6467_CR91","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/rheumatology\/key006","volume":"58","author":"SJ Carter","year":"2019","unstructured":"Carter SJ, Tattersall RS, Ramanan AV (2019) Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology (Oxford) 58(1):5\u201317. https:\/\/doi.org\/10.1093\/rheumatology\/key006","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"6467_CR92","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ (2018) Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.148","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"6467_CR93","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.Cd-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zheng Z, Rose-John S, White JC, Nazimuddin F, Wertheim G, Levine BL, June CH, Porter DL, Grupp SA (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6(6):664\u2013679. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-0040","journal-title":"Cancer Discov"},{"issue":"4","key":"6467_CR94","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1128\/cvi.00306-10","volume":"18","author":"MF Ibarra","year":"2011","unstructured":"Ibarra MF, Klein-Gitelman M, Morgan E, Proytcheva M, Sullivan C, Morgan G, Pachman LM, O\u2019Gorman MR (2011) Serum neopterin levels as a diagnostic marker of hemophagocytic lymphohistiocytosis syndrome. Clin Vaccine Immunol 18(4):609\u2013614. https:\/\/doi.org\/10.1128\/cvi.00306-10","journal-title":"Clin Vaccine Immunol"},{"issue":"3","key":"6467_CR95","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","volume":"104","author":"MB Jordan","year":"2004","unstructured":"Jordan MB, Hildeman D, Kappler J, Marrack P (2004) An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8\u2009+\u2009T cells and interferon gamma are essential for the disorder. Blood 104(3):735\u2013743. https:\/\/doi.org\/10.1182\/blood-2003-10-3413","journal-title":"Blood"},{"issue":"11","key":"6467_CR96","doi-asserted-by":"publisher","first-page":"e28581","DOI":"10.1002\/pbc.28581","volume":"67","author":"S Bami","year":"2020","unstructured":"Bami S, Vagrecha A, Soberman D, Badawi M, Cannone D, Lipton JM, Cron RQ, Levy CF (2020) The use of Anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 67(11):e28581. https:\/\/doi.org\/10.1002\/pbc.28581","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"6467_CR97","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/ejh.14029","volume":"111","author":"JEG Charlesworth","year":"2023","unstructured":"Charlesworth JEG, Kavirayani A (2023) Intravenous Anakinra for the treatment of haemophagocytic lymphohistiocytosis\/macrophage activation syndrome: a systematic review. Eur J Haematol 111(3):458\u2013476. https:\/\/doi.org\/10.1111\/ejh.14029","journal-title":"Eur J Haematol"},{"issue":"6","key":"6467_CR98","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1016\/s2665-9913(20)30096-5","volume":"2","author":"P Mehta","year":"2020","unstructured":"Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS (2020) Silencing the cytokine storm: the use of intravenous Anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol 2(6):e358\u2013e367. https:\/\/doi.org\/10.1016\/s2665-9913(20)30096-5","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"6467_CR99","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1167\/iovs.07-0273","volume":"49","author":"A Nehm\u00e9","year":"2008","unstructured":"Nehm\u00e9 A, Edelman J (2008) Dexamethasone inhibits high glucose-, TNF-alpha-, and IL-1beta-induced secretion of inflammatory and angiogenic mediators from retinal microvascular pericytes. Invest Ophthalmol Vis Sci 49(5):2030\u20132038. https:\/\/doi.org\/10.1167\/iovs.07-0273","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6467_CR100","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cytogfr.2016.05.002","volume":"31","author":"J Banuelos","year":"2016","unstructured":"Banuelos J, Lu NZ (2016) A gradient of glucocorticoid sensitivity among helper T cell cytokines. Cytokine Growth Factor Rev 31:27\u201335. https:\/\/doi.org\/10.1016\/j.cytogfr.2016.05.002","journal-title":"Cytokine Growth Factor Rev"},{"issue":"26","key":"6467_CR101","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127(26):3321\u20133330. https:\/\/doi.org\/10.1182\/blood-2016-04-703751","journal-title":"Blood"},{"key":"6467_CR102","doi-asserted-by":"publisher","unstructured":"Lakomy T, Akhoundova D, Nilius H, Kronig MN, Novak U, Daskalakis M, Bacher U, Pabst T (2023) Early use of corticosteroids following CAR T-cell therapy correlates with reduced risk of High-Grade CRS without negative impact on neurotoxicity or treatment outcome. Biomolecules 13(2). https:\/\/doi.org\/10.3390\/biom13020382","DOI":"10.3390\/biom13020382"},{"issue":"2","key":"6467_CR103","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00063-021-00781-9","volume":"116","author":"DA Eichenauer","year":"2021","unstructured":"Eichenauer DA, Lachmann G, La Ros\u00e9e P (2021) [Hemophagocytic lymphohistiocytosis in critically ill patients]. Med Klin Intensivmed Notfmed 116(2):129\u2013134. https:\/\/doi.org\/10.1007\/s00063-021-00781-9","journal-title":"Med Klin Intensivmed Notfmed"},{"issue":"177","key":"6467_CR104","doi-asserted-by":"publisher","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5(177):177ra138. https:\/\/doi.org\/10.1126\/scitranslmed.3005930","journal-title":"Sci Transl Med"},{"issue":"23","key":"6467_CR105","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1182\/blood.2020008865","volume":"137","author":"P Strati","year":"2021","unstructured":"Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, Neelapu SS (2021) Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood 137(23):3272\u20133276. https:\/\/doi.org\/10.1182\/blood.2020008865","journal-title":"Blood"},{"issue":"2","key":"6467_CR106","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-020-0280-y","volume":"10","author":"S Liu","year":"2020","unstructured":"Liu S, Deng B, Yin Z, Pan J, Lin Y, Ling Z, Wu T, Chen D, Chang AH, Gao Z, Song Y, Zhao Y, Tong C (2020) Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J 10(2):15. https:\/\/doi.org\/10.1038\/s41408-020-0280-y","journal-title":"Blood Cancer J"},{"issue":"4","key":"6467_CR107","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, Bhatia S, Budde LE, Chokshi S, Davies M, Elshoury A, Gesthalter Y, Hegde A, Jain M, Kaffenberger BH, Lechner MG, Li T, Marr A, McGettigan S, McPherson J, Medina T, Mohindra NA, Olszanski AJ, Oluwole O, Patel SP, Patil P, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Zaha VG, Lyons M, Dwyer M, Hang L (2022) Management of Immunotherapy-Related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20(4):387\u2013405. https:\/\/doi.org\/10.6004\/jnccn.2022.0020","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"6467_CR108","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1097\/ccm.0000000000002053","volume":"45","author":"JC Fitzgerald","year":"2017","unstructured":"Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, Shaw P, Berg RA, June CH, Porter DL, Frey NV, Grupp SA, Teachey DT (2017) Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med 45(2):e124\u2013e131. https:\/\/doi.org\/10.1097\/ccm.0000000000002053","journal-title":"Crit Care Med"},{"issue":"8","key":"6467_CR109","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/phar.2414","volume":"40","author":"CW Freyer","year":"2020","unstructured":"Freyer CW, Porter DL (2020) Advances in CAR T therapy for hematologic malignancies. Pharmacotherapy 40(8):741\u2013755. https:\/\/doi.org\/10.1002\/phar.2414","journal-title":"Pharmacotherapy"},{"issue":"20","key":"6467_CR110","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1182\/blood.2022017414","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN (2023) How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood 141(20):2430\u20132442. https:\/\/doi.org\/10.1182\/blood.2022017414","journal-title":"Blood"},{"key":"6467_CR111","doi-asserted-by":"publisher","first-page":"745320","DOI":"10.3389\/fimmu.2021.745320","volume":"12","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Pacheco Sanchez G, Sharma A, Otegbeye F, Ahmed N, Rojas P, Patel S, Kleinsorge Block S, Schiavone J, Zamborsky K, Boughan K, Hillian A, Reese-Koc J, Maschan M, Dropulic B, Sekaly RP, de Lima M (2021) Prophylactic Tocilizumab prior to Anti-CD19 CAR-T cell therapy for Non-Hodgkin lymphoma. Front Immunol 12:745320. https:\/\/doi.org\/10.3389\/fimmu.2021.745320","journal-title":"Front Immunol"},{"key":"6467_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2016.03.005","volume":"434","author":"F Chen","year":"2016","unstructured":"Chen F, Teachey DT, Pequignot E, Frey N, Porter D, Maude SL, Grupp SA, June CH, Melenhorst JJ, Lacey SF (2016) Measuring IL-6 and sIL-6R in serum from patients treated with Tocilizumab and\/or Siltuximab following CAR T cell therapy. J Immunol Methods 434:1\u20138. https:\/\/doi.org\/10.1016\/j.jim.2016.03.005","journal-title":"J Immunol Methods"},{"issue":"10","key":"6467_CR113","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","volume":"22","author":"R Abboud","year":"2016","unstructured":"Abboud R, Keller J, Slade M, DiPersio JF, Westervelt P, Rettig MP, Meier S, Fehniger TA, Abboud CN, Uy GL, Vij R, Trinkaus KM, Schroeder MA, Romee R (2016) Severe Cytokine-Release syndrome after T Cell-Replete peripheral blood haploidentical donor transplantation is associated with poor survival and Anti-IL-6 therapy is safe and well tolerated. Biol Blood Marrow Transpl 22(10):1851\u20131860. https:\/\/doi.org\/10.1016\/j.bbmt.2016.06.010","journal-title":"Biol Blood Marrow Transpl"},{"key":"6467_CR114","doi-asserted-by":"publisher","unstructured":"Ferreros P, Trapero I (2022) Interleukin inhibitors in cytokine release syndrome and neurotoxicity secondary to CAR-T therapy. Diseases 10(3). https:\/\/doi.org\/10.3390\/diseases10030041","DOI":"10.3390\/diseases10030041"},{"issue":"9","key":"6467_CR115","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/s41551-023-01084-4","volume":"7","author":"X Li","year":"2023","unstructured":"Li X, Gong N, Tian F, Zhang S, Zhang Y, Wang Y, Qing G, Wang Y, Li F, Xu Y, Zhang L, Wang J, Ni Q, Gan Y, Gu C, Jiang H, Huang X, Shi X, Zhang T, Wu Y, Liang XJ (2023) Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel. Nat Biomed Eng 7(9):1129\u20131141. https:\/\/doi.org\/10.1038\/s41551-023-01084-4","journal-title":"Nat Biomed Eng"},{"issue":"7","key":"6467_CR116","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","volume":"29","author":"JH Park","year":"2023","unstructured":"Park JH, Nath K, Devlin SM, Sauter CS, Palomba ML, Shah G, Dahi P, Lin RJ, Scordo M, Perales MA, Shouval R, Tomas AA, Cathcart E, Mead E, Santomasso B, Holodny A, Brentjens RJ, Riviere I, Sadelain M (2023) CD19 CAR T-cell therapy and prophylactic Anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med 29(7):1710\u20131717. https:\/\/doi.org\/10.1038\/s41591-023-02404-6","journal-title":"Nat Med"},{"key":"6467_CR117","doi-asserted-by":"publisher","unstructured":"Wehrli M, Gallagher K, Chen YB, Leick MB, McAfee SL, El-Jawahri AR, DeFilipp Z, Horick N, O\u2019Donnell P, Spitzer T, Dey B, Cook D, Trailor M, Lindell K, Maus MV, Frigault MJ (2022) Single-center experience using Anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J Immunother Cancer 10(1). https:\/\/doi.org\/10.1136\/jitc-2021-003847","DOI":"10.1136\/jitc-2021-003847"},{"issue":"7","key":"6467_CR118","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","volume":"29","author":"N Gazeau","year":"2023","unstructured":"Gazeau N, Liang EC, Wu QV, Voutsinas JM, Barba P, Iacoboni G, Kwon M, Ortega JLR, L\u00f3pez-Corral L, Hernani R, Ortiz-Maldonado V, Mart\u00ednez-Cibrian N, Martinez AP, Maziarz RT, Williamson S, Nemecek ER, Shadman M, Cowan AJ, Green DJ, Kimble E, Hirayama AV, Maloney DG, Turtle CJ, Gauthier J (2023) Anakinra for refractory cytokine release syndrome or immune effector cell-Associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy. Transplantation Cell Therapy 29(7):430\u2013437. https:\/\/doi.org\/10.1016\/j.jtct.2023.04.001","journal-title":"Transplantation Cell Therapy"},{"key":"6467_CR119","doi-asserted-by":"publisher","unstructured":"Baverez C, Grall M, Gerfaud-Valentin M, De Gail S, Belot A, Perpoint T, Weber E, Reynaud Q, S\u00e8ve P, Jamilloux Y (2022) Anakinra for the treatment of hemophagocytic lymphohistiocytosis: 21 cases. J Clin Med 11(19). https:\/\/doi.org\/10.3390\/jcm11195799","DOI":"10.3390\/jcm11195799"},{"issue":"2","key":"6467_CR120","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","volume":"50","author":"PM Miettunen","year":"2011","unstructured":"Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ (2011) Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 Inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 50(2):417\u2013419. https:\/\/doi.org\/10.1093\/rheumatology\/keq218","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"6467_CR121","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","volume":"12","author":"AA Grom","year":"2016","unstructured":"Grom AA, Horne A, De Benedetti F (2016) Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 12(5):259\u2013268. https:\/\/doi.org\/10.1038\/nrrheum.2015.179","journal-title":"Nat Rev Rheumatol"},{"key":"6467_CR122","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O\u2019Shea","year":"2015","unstructured":"O\u2019Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A (2015) The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 66:311\u2013328. https:\/\/doi.org\/10.1146\/annurev-med-051113-024537","journal-title":"Annu Rev Med"},{"issue":"Suppl 1","key":"6467_CR123","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","volume":"58","author":"M Gadina","year":"2019","unstructured":"Gadina M, Le MT, Schwartz DM, Silvennoinen O, Nakayamada S, Yamaoka K, O\u2019Shea JJ (2019) Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology (Oxford) 58(Suppl 1):i4\u2013i16. https:\/\/doi.org\/10.1093\/rheumatology\/key432","journal-title":"Rheumatology (Oxford)"},{"issue":"23","key":"6467_CR124","doi-asserted-by":"publisher","first-page":"6299","DOI":"10.1158\/1078-0432.Ccr-20-1739","volume":"26","author":"E Huarte","year":"2020","unstructured":"Huarte E, O\u2019Connor RS, Peel MT, Nunez-Cruz S, Leferovich J, Juvekar A, Yang YO, Truong L, Huang T, Naim A, Milone MC, Smith PA (2020) Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy. Clin Cancer Res: Off J Am Assoc Cancer Res 26(23):6299\u20136309. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-1739","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"6467_CR125","doi-asserted-by":"publisher","first-page":"614704","DOI":"10.3389\/fimmu.2021.614704","volume":"12","author":"C Keenan","year":"2021","unstructured":"Keenan C, Nichols KE, Albeituni S (2021) Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis. Front Immunol 12:614704. https:\/\/doi.org\/10.3389\/fimmu.2021.614704","journal-title":"Front Immunol"},{"issue":"13","key":"6467_CR126","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood-2015-12-684399","volume":"127","author":"R Das","year":"2016","unstructured":"Das R, Guan P, Sprague L, Verbist K, Tedrick P, An QA, Cheng C, Kurachi M, Levine R, Wherry EJ, Canna SW, Behrens EM, Nichols KE (2016) Janus kinase Inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood 127(13):1666\u20131675. https:\/\/doi.org\/10.1182\/blood-2015-12-684399","journal-title":"Blood"},{"issue":"1","key":"6467_CR127","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1182\/blood-2016-02-700013","volume":"128","author":"S Maschalidi","year":"2016","unstructured":"Maschalidi S, Sepulveda FE, Garrigue A, Fischer A, de Saint Basile G (2016) Therapeutic effect of JAK1\/2 Blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood 128(1):60\u201371. https:\/\/doi.org\/10.1182\/blood-2016-02-700013","journal-title":"Blood"},{"issue":"4","key":"6467_CR128","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1177\/1078155219878774","volume":"26","author":"T Trantham","year":"2020","unstructured":"Trantham T, Auten J, Muluneh B, Van Deventer H (2020) Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: a cautionary tale. J Oncol Pharm Pract 26(4):1005\u20131008. https:\/\/doi.org\/10.1177\/1078155219878774","journal-title":"J Oncol Pharm Pract"},{"key":"6467_CR129","doi-asserted-by":"publisher","unstructured":"Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, Mades A, Sadelain M, Einsele H, Hudecek M (2019) The tyrosine kinase inhibitor dasatinib acts as a Pharmacologic on\/off switch for CAR T cells. Sci Transl Med 11(499). https:\/\/doi.org\/10.1126\/scitranslmed.aau5907","DOI":"10.1126\/scitranslmed.aau5907"},{"issue":"5","key":"6467_CR130","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/bjh.15975","volume":"186","author":"F Fasslrinner","year":"2019","unstructured":"Fasslrinner F, Arndt C, Koristka S, Feldmann A, Altmann H, von Bonin M, Schmitz M, Bornh\u00e4user M, Bachmann M (2019) Midostaurin abrogates CD33-directed unicar and CD33-CD3 bispecific antibody therapy in acute myeloid leukaemia. Br J Haematol 186(5):735\u2013740. https:\/\/doi.org\/10.1111\/bjh.15975","journal-title":"Br J Haematol"},{"issue":"8","key":"6467_CR131","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1172\/jci89756","volume":"127","author":"M Long","year":"2017","unstructured":"Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, Woyach JA, Caligiuri MA, Johnson AJ, Muthusamy N, Byrd JC (2017) Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest 127(8):3052\u20133064. https:\/\/doi.org\/10.1172\/jci89756","journal-title":"J Clin Invest"},{"issue":"20","key":"6467_CR132","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.18632\/oncotarget.26744","volume":"10","author":"I Ferrarini","year":"2019","unstructured":"Ferrarini I, Rigo A, Montresor A, Laudanna C, Vinante F (2019) Monocyte-to-macrophage switch reversibly impaired by ibrutinib. Oncotarget 10(20):1943\u20131956. https:\/\/doi.org\/10.18632\/oncotarget.26744","journal-title":"Oncotarget"},{"issue":"1","key":"6467_CR133","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/leu.2016.262","volume":"31","author":"M Ruella","year":"2017","unstructured":"Ruella M, Kenderian SS, Shestova O, Klichinsky M, Melenhorst JJ, Wasik MA, Lacey SF, June CH, Gill S (2017) Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Leukemia 31(1):246\u2013248. https:\/\/doi.org\/10.1038\/leu.2016.262","journal-title":"Leukemia"},{"issue":"19","key":"6467_CR134","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood.2019002936","volume":"135","author":"J Gauthier","year":"2020","unstructured":"Gauthier J, Hirayama AV, Purushe J, Hay KA, Lymp J, Li DH, Yeung CCS, Sheih A, Pender BS, Hawkins RM, Vakil A, Phi TD, Steinmetz RN, Shadman M, Riddell SR, Maloney DG, Turtle CJ (2020) Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood 135(19):1650\u20131660. https:\/\/doi.org\/10.1182\/blood.2019002936","journal-title":"Blood"},{"issue":"3","key":"6467_CR135","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.transci.2019.04.007","volume":"58","author":"M Fern\u00e1ndez-Zarzoso","year":"2019","unstructured":"Fern\u00e1ndez-Zarzoso M, G\u00f3mez-Segu\u00ed I, de la Rubia J (2019) Therapeutic plasma exchange: review of current indications. Transfus Apher Sci 58(3):247\u2013253. https:\/\/doi.org\/10.1016\/j.transci.2019.04.007","journal-title":"Transfus Apher Sci"},{"issue":"3","key":"6467_CR136","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","volume":"4","author":"R Awasthi","year":"2020","unstructured":"Awasthi R, Pacaud L, Waldron E, Tam CS, J\u00e4ger U, Borchmann P, Jaglowski S, Foley SR, van Besien K, Wagner-Johnston ND, Kersten MJ, Schuster SJ, Salles G, Maziarz RT, Anak \u00d6, Del Corral C, Chu J, Gershgorin I, Pruteanu-Malinici I, Chakraborty A, Mueller KT, Waller EK (2020) Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL. Blood Adv 4(3):560\u2013572. https:\/\/doi.org\/10.1182\/bloodadvances.2019000525","journal-title":"Blood Adv"},{"issue":"2","key":"6467_CR137","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/ejh.13248","volume":"103","author":"A Sindel","year":"2019","unstructured":"Sindel A, Taylor T, Chesney A, Clark W, Fowler AA 3rd, Toor AA (2019) Hematopoietic stem cell mobilization following PD-1 blockade: cytokine release syndrome after transplantation managed with ascorbic acid. Eur J Haematol 103(2):134\u2013136. https:\/\/doi.org\/10.1111\/ejh.13248","journal-title":"Eur J Haematol"},{"issue":"10","key":"6467_CR138","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1007\/s00134-022-06793-z","volume":"48","author":"PR Bauer","year":"2022","unstructured":"Bauer PR, Ostermann M, Russell L, Robba C, David S, Ferreyro BL, Cid J, Castro P, Juffermans NP, Montini L, Pirani T, Van De Louw A, Nielsen N, Wendon J, Brignier AC, Schetz M, Kielstein JT, Winters JL, Azoulay E (2022) Plasma exchange in the intensive care unit: a narrative review. Intensive Care Med 48(10):1382\u20131396. https:\/\/doi.org\/10.1007\/s00134-022-06793-z","journal-title":"Intensive Care Med"},{"key":"6467_CR139","doi-asserted-by":"publisher","first-page":"111761","DOI":"10.1016\/j.intimp.2024.111761","volume":"130","author":"Y Pu","year":"2024","unstructured":"Pu Y, Zhao Y, Qi Y, Liu Y, Zhang M, Xiao X, Lyu H, Meng J, Zhu H, Xu K, Han W, Zhao M (2024) Multi-centers experience using therapeutic plasma exchange for corticosteroid\/tocilizumab-refractory cytokine release syndrome following CAR-T therapy. Int Immunopharmacol 130:111761. https:\/\/doi.org\/10.1016\/j.intimp.2024.111761","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"6467_CR140","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.transci.2016.09.015","volume":"55","author":"M Bosnak","year":"2016","unstructured":"Bosnak M, Erdogan S, Aktekin EH, Bay A (2016) Therapeutic plasma exchange in primary hemophagocytic lymphohistiocytosis: reports of two cases and a review of the literature. Transfus Apher Sci 55(3):353\u2013356. https:\/\/doi.org\/10.1016\/j.transci.2016.09.015","journal-title":"Transfus Apher Sci"},{"issue":"5","key":"6467_CR141","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/jamaoncol.2022.0070","volume":"8","author":"JC Zurko","year":"2022","unstructured":"Zurko JC, Johnson BD, Aschenbrenner E, Fenske TS, Hamadani M, Hari P, Shah NN (2022) Use of early intrathecal therapy to manage High-Grade immune effector Cell-Associated neurotoxicity syndrome. JAMA Oncol 8(5):773\u2013775. https:\/\/doi.org\/10.1001\/jamaoncol.2022.0070","journal-title":"JAMA Oncol"},{"key":"6467_CR142","doi-asserted-by":"publisher","first-page":"1380451","DOI":"10.3389\/fimmu.2024.1380451","volume":"15","author":"M Katsin","year":"2024","unstructured":"Katsin M, Shman T, Migas A, Lutskovich D, Serada Y, Khalankova Y, Kostina Y, Dubovik S (2024) Case report: rapid resolution of grade IV ICANS after first line intrathecal chemotherapy with methotrexate, cytarabine and dexamethasone. Front Immunol 15:1380451. https:\/\/doi.org\/10.3389\/fimmu.2024.1380451","journal-title":"Front Immunol"},{"issue":"1","key":"6467_CR143","doi-asserted-by":"publisher","first-page":"e30741","DOI":"10.1002\/pbc.30741","volume":"71","author":"H Shalabi","year":"2024","unstructured":"Shalabi H, Harrison C, Yates B, Calvo KR, Lee DW, Shah NN (2024) Intrathecal hydrocortisone for treatment of children and young adults with CAR T-cell immune-effector cell-associated neurotoxicity syndrome. Pediatr Blood Cancer 71(1):e30741. https:\/\/doi.org\/10.1002\/pbc.30741","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"6467_CR144","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/ped.14172","volume":"62","author":"N Kajita","year":"2020","unstructured":"Kajita N, Saito Y, Makimoto A, Miyahara S, Yuza Y (2020) Double recurrence of double cancers: rhabdomyosarcoma and secondary AML. Pediatr Int 62(6):742\u2013744. https:\/\/doi.org\/10.1111\/ped.14172","journal-title":"Pediatr Int"},{"key":"6467_CR145","doi-asserted-by":"publisher","first-page":"156234","DOI":"10.1016\/j.cyto.2023.156234","volume":"168","author":"C Bailly","year":"2023","unstructured":"Bailly C (2023) Etoposide: a rider on the cytokine storm. Cytokine 168:156234. https:\/\/doi.org\/10.1016\/j.cyto.2023.156234","journal-title":"Cytokine"},{"issue":"3","key":"6467_CR146","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1182\/blood.2021013549","volume":"140","author":"A De Matteis","year":"2022","unstructured":"De Matteis A, Colucci M, Rossi MN, Caiello I, Merli P, Tumino N, Bertaina V, Pardeo M, Bracaglia C, Locatelli F, De Benedetti F, Prencipe G (2022) Expansion of CD4dimCD8\u2009+\u2009T cells characterizes macrophage activation syndrome and other secondary HLH. Blood 140(3):262\u2013273. https:\/\/doi.org\/10.1182\/blood.2021013549","journal-title":"Blood"},{"issue":"8","key":"6467_CR147","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3324\/haematol.2015.123562","volume":"100","author":"K Lehmberg","year":"2015","unstructured":"Lehmberg K, Nichols KE, Henter JI, Girschikofsky M, Greenwood T, Jordan M, Kumar A, Minkov M, La Ros\u00e9e P, Weitzman S (2015) Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. Haematologica 100(8):997\u20131004. https:\/\/doi.org\/10.3324\/haematol.2015.123562","journal-title":"Haematologica"},{"key":"6467_CR148","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2147\/ijgm.S443774","volume":"17","author":"K Lv","year":"2024","unstructured":"Lv K, Cheng X, Zhou Y, Yu M, Wang S, Shen H, Li F (2024) Patients with hemophagocytic lymphohistiocytosis who need intensive care can be successfully rescued by timely using Etoposide-Based HLH regimens. Int J Gen Med 17:431\u2013446. https:\/\/doi.org\/10.2147\/ijgm.S443774","journal-title":"Int J Gen Med"},{"issue":"1","key":"6467_CR149","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-018-1046-8","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama ZT (2019) Emapalumab: first global approval. Drugs 79(1):99\u2013103. https:\/\/doi.org\/10.1007\/s40265-018-1046-8","journal-title":"Drugs"},{"issue":"19","key":"6467_CR150","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","volume":"382","author":"F Locatelli","year":"2020","unstructured":"Locatelli F, Jordan MB, Allen C, Cesaro S, Rizzari C, Rao A, Degar B, Garrington TP, Sevilla J, Putti MC, Fagioli F, Ahlmann M, Dapena Diaz JL, Henry M, De Benedetti F, Grom A, Lapeyre G, Jacqmin P, Ballabio M, de Min C (2020) Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med 382(19):1811\u20131822. https:\/\/doi.org\/10.1056\/NEJMoa1911326","journal-title":"N Engl J Med"},{"issue":"7","key":"6467_CR151","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1177\/10600280221134719","volume":"57","author":"J Summerlin","year":"2023","unstructured":"Summerlin J, Wells DA, Anderson MK, Halford Z (2023) A review of current and emerging therapeutic options for hemophagocytic lymphohistiocytosis. Ann Pharmacother 57(7):867\u2013879. https:\/\/doi.org\/10.1177\/10600280221134719","journal-title":"Ann Pharmacother"},{"issue":"6","key":"6467_CR152","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/ard-2022-223739","volume":"82","author":"F De Benedetti","year":"2023","unstructured":"De Benedetti F, Grom AA, Brogan PA, Bracaglia C, Pardeo M, Marucci G, Eleftheriou D, Papadopoulou C, Schulert GS, Quartier P, Ant\u00f3n J, Laveille C, Frederiksen R, Asnaghi V, Ballabio M, Jacqmin P, de Min C (2023) Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis 82(6):857\u2013865. https:\/\/doi.org\/10.1136\/ard-2022-223739","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6467_CR153","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1038\/s41467-023-38723-y","volume":"14","author":"S Manni","year":"2023","unstructured":"Manni S, Del Bufalo F, Merli P, Silvestris DA, Guercio M, Caruso S, Reddel S, Iaffaldano L, Pezzella M, Di Cecca S, Sinibaldi M, Ottaviani A, Quadraccia MC, Aurigemma M, Sarcinelli A, Ciccone R, Abbaszadeh Z, Ceccarelli M, De Vito R, Lodi MC, Cefalo MG, Mastronuzzi A, De Angelis B, Locatelli F, Quintarelli C (2023) Neutralizing IFN\u03b3 improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies. Nat Commun 14(1):3423. https:\/\/doi.org\/10.1038\/s41467-023-38723-y","journal-title":"Nat Commun"},{"issue":"5","key":"6467_CR154","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.immuni.2016.10.026","volume":"45","author":"B Becher","year":"2016","unstructured":"Becher B, Tugues S, Greter M (2016) GM-CSF: from growth factor to central mediator of tissue inflammation. Immunity 45(5):963\u2013973. https:\/\/doi.org\/10.1016\/j.immuni.2016.10.026","journal-title":"Immunity"},{"issue":"9","key":"6467_CR155","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.2019002121","volume":"135","author":"O Dufva","year":"2020","unstructured":"Dufva O, Koski J, Maliniemi P, Ianevski A, Klievink J, Leitner J, P\u00f6l\u00f6nen P, Hohtari H, Saeed K, Hannunen T, Ellonen P, Steinberger P, Kankainen M, Aittokallio T, Ker\u00e4nen MAI, Korhonen M, Mustjoki S (2020) Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood 135(9):597\u2013609. https:\/\/doi.org\/10.1182\/blood.2019002121","journal-title":"Blood"},{"key":"6467_CR156","doi-asserted-by":"publisher","unstructured":"Leclercq G, Haegel H, Toso A, Zimmermann T, Green L, Steinhoff N, Sam J, Pulko V, Schneider A, Giusti AM, Challier J, Freimoser-Grundschober A, Larivi\u00e8re L, Odermatt A, Stern M, Umana P, Bacac M, Klein C (2022) JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy. J Immunother Cancer 10(1). https:\/\/doi.org\/10.1136\/jitc-2021-003766","DOI":"10.1136\/jitc-2021-003766"},{"issue":"3","key":"6467_CR157","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/jcp.30008","volume":"236","author":"A Vecchi\u00e9","year":"2021","unstructured":"Vecchi\u00e9 A, Bonaventura A, Toldo S, Dagna L, Dinarello CA, Abbate A (2021) IL-18 and infections: is there a role for targeted therapies? J Cell Physiol 236(3):1638\u20131657. https:\/\/doi.org\/10.1002\/jcp.30008","journal-title":"J Cell Physiol"},{"issue":"4","key":"6467_CR158","doi-asserted-by":"publisher","first-page":"e0231896","DOI":"10.1371\/journal.pone.0231896","volume":"15","author":"M Futami","year":"2020","unstructured":"Futami M, Suzuki K, Kato S, Ohmae S, Tahara Y, Nojima M, Imai Y, Mimura T, Watanabe Y, Tojo A (2020) The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells. PLoS ONE 15(4):e0231896. https:\/\/doi.org\/10.1371\/journal.pone.0231896","journal-title":"PLoS ONE"},{"issue":"1","key":"6467_CR159","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-020-01301-7","volume":"20","author":"Y Wei","year":"2021","unstructured":"Wei Y, Li C, Bian H, Qian W, Jin K, Xu T, Guo X, Lu X, Su F (2021) Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome. Mol Cancer 20(1):5. https:\/\/doi.org\/10.1186\/s12943-020-01301-7","journal-title":"Mol Cancer"},{"key":"6467_CR160","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.omto.2021.08.014","volume":"23","author":"M Sun","year":"2021","unstructured":"Sun M, Xu P, Wang E, Zhou M, Xu T, Wang J, Wang Q, Wang B, Lu K, Wang C, Chen B (2021) Novel two-chain structure utilizing KIRS2\/DAP12 domain improves the safety and efficacy of CAR-T cells in adults with r\/r B-ALL. Mol Ther Oncolytics 23:96\u2013106. https:\/\/doi.org\/10.1016\/j.omto.2021.08.014","journal-title":"Mol Ther Oncolytics"},{"key":"6467_CR161","doi-asserted-by":"publisher","first-page":"765097","DOI":"10.3389\/fimmu.2021.765097","volume":"12","author":"P Safarzadeh Kozani","year":"2021","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F (2021) Optimizing the clinical impact of CAR-T cell therapy in B-Cell acute lymphoblastic leukemia: looking back while moving forward. Front Immunol 12:765097. https:\/\/doi.org\/10.3389\/fimmu.2021.765097","journal-title":"Front Immunol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06467-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06467-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06467-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T20:24:36Z","timestamp":1757190276000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06467-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":161,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["6467"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06467-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}